*CUPRINA FORMS JOINT VENTURE COMPANY WITH AIODINE LABORATORY TO DEVELOP AND MARKET NOVEL IODINE-BASED SOLUTION AS NEW WOUND CARE THERAPY
*CUPRINA HOLDINGS (CAYMAN) LTD - CLINICAL STUDIES FOR REGULATORY APPROVALS PLANNED FOR 2026
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 18-NOV-202513:30:00.627 GMT